1 Genomics and Microbiome Science, DuPont Nutrition & Health, 4300 Duncan Avenue, Saint Louis, MO 63110, USA.
2 DuPont Nutrition Biosciences ApS, Edwin Rahrsvej 38, 8220 Brabrand, Aarhus, Denmark.
Benef Microbes. 2019 Mar 13;10(2):121-135. doi: 10.3920/BM2018.0028. Epub 2018 Dec 10.
The gut microbiota contributes to host energy metabolism, and altered gut microbiota has been associated with obesity-related metabolic disorders. We previously reported that a probiotic alone or together with a prebiotic controls body fat mass in healthy overweight or obese individuals in a randomised, double-blind, placebo controlled clinical study (ClinicalTrials.gov NCT01978691). We now aimed to investigate whether changes in the gut microbiota may be associated with the observed clinical benefits. Faecal and plasma samples were obtained from a protocol compliant subset (n=134) of participants from a larger clinical study where participants were randomised (1:1:1:1) into four groups: (1) placebo, 12 g/d microcrystalline cellulose; (2) Litesse® Ultra™ polydextrose (LU), 12 g/day; (3) Bifidobacterium animalis subsp. lactis 420™ (B420), 10 cfu/d in 12 g microcrystalline cellulose; (4) LU+B420, 1010 cfu/d of B420 in 12 g/d LU for 6 months of intervention. The faecal microbiota composition and metabolites were assessed as exploratory outcomes at baseline, 2, 4, 6 months, and +1 month post-intervention and correlated to obesity-related clinical outcomes. Lactobacillus and Akkermansia were more abundant with B420 at the end of the intervention. LU+B420 increased Akkermansia, Christensenellaceae and Methanobrevibacter, while Paraprevotella was reduced. Christensenellaceae was consistently increased in the LU and LU+B420 groups across the intervention time points, and correlated negatively to waist-hip ratio and energy intake at baseline, and waist-area body fat mass after 6 months treatment with LU+B420. Functional metagenome predictions indicated alterations in pathways related to cellular processes and metabolism. Plasma bile acids glycocholic acid, glycoursodeoxycholic acid, and taurohyodeoxycholic acid and tauroursodeoxycholic acid were reduced in LU+B420 compared to Placebo. Consumption of B420 and its combination with LU resulted in alterations of the gut microbiota and its metabolism, and may support improved gut barrier function and obesity-related markers.
肠道微生物群有助于宿主的能量代谢，而改变的肠道微生物群与肥胖相关的代谢紊乱有关。我们之前的研究报告称，在一项随机、双盲、安慰剂对照的临床研究（ClinicalTrials.gov NCT01978691）中，益生菌单独或与益生元一起可控制健康超重或肥胖个体的体脂肪量。我们现在旨在研究肠道微生物群的变化是否与观察到的临床益处相关。从更大规模的临床研究中符合方案的亚组（n=134）参与者中获取粪便和血浆样本，参与者随机分为四组（1:1:1:1）：（1）安慰剂，12g/d 微晶纤维素；（2）Litesse® Ultra™聚右旋糖（LU），12g/天；（3）乳双歧杆菌亚种。420™（B420），10cfu/d 在 12g 微晶纤维素中；（4）LU+B420，12g/d LU 中含有 1010cfu/d 的 B420，干预 6 个月。在基线、2、4、6 个月和干预后+1 个月时，评估粪便微生物群组成和代谢物作为探索性结果，并与肥胖相关的临床结果相关。在干预结束时，B420 使乳杆菌和阿克曼氏菌更丰富。LU+B420 增加阿克曼氏菌、克里斯滕森菌科和甲烷短杆菌，而副拟杆菌减少。在整个干预时间点，LU 和 LU+B420 组中克里斯滕森菌科持续增加，与基线时的腰臀比和能量摄入呈负相关，与 6 个月时的 LU+B420 治疗后的腰区体脂肪量相关。功能宏基因组预测表明与细胞过程和代谢相关的途径发生改变。与安慰剂相比，LU+B420 中胆汁酸甘胆酸、甘氨脱氧胆酸和牛磺脱氧胆酸和牛磺熊脱氧胆酸的血浆水平降低。B420 的消耗及其与 LU 的组合导致肠道微生物群及其代谢的改变，并可能支持改善肠道屏障功能和肥胖相关标志物。
